BioSpace News Archive

Indivior today announces that the FDA has accepted the NDA for RBP-7000, an investigational, once-monthly injectable risperidone in the ATRIGEL delivery system for the treatment of schizophrenia.

Poised to launch, the product will be sold in 1 mL single-dose vials as well as in 5 mL and 10 mL multiple dose vials.

This translational research provides important evidence that elucidates how treatment with GMI-1271 appears to be improving sensitivity to chemotherapy.

Relevium announce it has strengthened its balance sheet through the partial conversion of debentures into equity, and increased its cash position through the exercise of warrants and options.

Janssen R&D today announced data from the Phase 3 ALCYONE study, showing that DARZALEX in combination with bortezomib, melphalan and prednisone significantly improved clinical outcomes, including reducing the risk of disease progression or death by 50 percent, in patients with newly diagnosed multiple myeloma who are ineligible for ASCT.

The transfer of the Lock-in Shares was agreed between Covington and Dermot Keane as an off-market transaction at a price of 36 pence per Lock-in Share.

Sectra has implemented its IT solution for breast imaging at St Marks Breast Centre in New Zealand.

CPI-1205 is a potent, highly selective, first-generation small-molecule inhibitor of EZH2, a clinically-validated target in cancer.

Neteera announced the addition of Jason Rudd and Ilya Vatsel to the company’s senior management team bringing a wealth of experience and know-how to the growing sensor technology company.

This agreement gives Palleon the exclusive rights to a patent portfolio that will facilitate the development of drugs that target Glycoimmune Checkpoints, a novel approach to overcoming resistance to first-generation immuno-oncology drugs.